Tuis532523 • BOM
add
Biocon Ltd
Vorige sluiting
₹323,15
Dagwisseling
₹322,45 - ₹332,30
Jaarwisseling
₹231,35 - ₹395,65
Markkapitalisasie
396,60 mjd INR
Gemiddelde volume
170,80 k
P/V-verhouding
27,55
Dividend-opbrengs
0,15%
Primêre beurs
NSE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(INR) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 35,90 mjd | 3,70% |
Bedryfskoste | 21,42 mjd | 8,03% |
Netto inkomste | -160,00 m | -112,74% |
Netto winsgrens | -0,45 | -112,40% |
Wins per aandeel | -0,19 | -115,53% |
EBITDA | 6,78 mjd | -6,58% |
Effektiewe belastingkoers | 72,46% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(INR) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 26,50 mjd | -30,00% |
Totale bates | 571,28 mjd | 4,67% |
Totale aanspreeklikheid | 304,08 mjd | 0,36% |
Totale ekwiteit | 267,20 mjd | — |
Uitstaande aandele | 1,23 mjd | — |
Prys om te bespreek | 1,89 | — |
Opbrengs op bates | — | — |
Opbrengs op kapitaal | 1,56% | — |
Kontantvloei
Netto kontantverandering
(INR) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -160,00 m | -112,74% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Gestig
1978
Hoofkwartier
Webwerf
Werknemers
16 315